JAZZ 外汇新闻
Jazz Pharma Says Phase 2b Trial Of Suvecaltamide In Essential Tremor Fails To Meet Primary Endpoint
Jazz Pharmaceuticals plc (JAZZ) announced Thursday top-line results from the Phase 2b clinical trial evaluating the efficacy and safety of suvecaltamide, an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET).
RTTNews
|
138天前
